Hans-Heinrich Oberg1†
Malte Deseke2†Steffen Krohn3†Dorothee Winterberg3
Matthias Peipp3Dirk Bauerschlag4
Klaus-Peter Künkele2
Daniela Wesch1*
Christoph Baumann2*- 1Institute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany
- 2Evobright GmbH, Vienna, Austria
- 3Division of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany
- 4Polyclinic and Clinic of Gynecology, University Center, Jena, Germany
By Oberg H-H, Deseke M, Krohn S, Winterberg D, Peipp M, Bauerschlag D, Künkele K-P, Wesch D and Baumann C (2025) Front. Immunol. 16:1628501. doi: 10.3389/fimmu.2025.1628501
In the published article, there was a mistake in the Materials and methods section. In the paragraph, Establishment of Vγ9Vδ2 T cell lines, there was an erraneous concentration of 2.5mM:
“Peripheral blood lymphocytes (PBL) were isolated from leukocyte concentrates or EDTA blood of healthy or ovarian cancer patient donors using Ficoll-Hypaque™ PLUS (Cytiva) density gradient centrifugation. A total of 1 x 106 PBMCs were stimulated with 2.5 mM of the aminobisphosphonate (n-BP) zoledronate (Novartis, Basel, Switzerland) in complete medium.
The complete culture medium for primary immune cell culture or assay setup was composed of RPMI 1640 supplemented with 2 mM L-glutamine, 25 mM HEPES, 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% FCS. All cell culture procedures and assay incubation steps were performed at 37°C in a humidified atmosphere with 5% CO2. Activation of PBL with n-BP and IL-2 induced selective activation and proliferation of Vγ9Vδ2 T cells. Recombinant IL-2 (Novartis) was added every 2 days at a concentration of 50 IU/mL for 14 days, as initially stimulated γδT cells produced only low levels of IL-2. After 14 days, the short-term activated γδ T cell lines were stained with the following antibodies: AF700-labeled anti-CD3 clone SK7 (BioLegend, San Diego, CA, USA); AF488-labeled anti-Vγ9 clone 7A5 (62) flow cytometry to determine purity. γδ T cells with a purity of >95% were used for functional assays”.
A correction has been made to the section Materials and methods, Establishment of Vγ9Vδ2 T cell lines:
“Peripheral blood lymphocytes (PBL) were isolated from leukocyte concentrates or EDTA blood of healthy or ovarian cancer patient donors using Ficoll-Hypaque™ PLUS (Cytiva) density gradient centrifugation. A total of 1 x 106 PBMCs were stimulated with 2.5 μM of the aminobisphosphonate (n-BP) zoledronate (Novartis, Basel, Switzerland) in complete medium.
The complete culture medium for primary immune cell culture or assay setup was composed of RPMI 1640 supplemented with 2 mM L-glutamine, 25 mM HEPES, 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% FCS. All cell culture procedures and assay incubation steps were performed at 37°C in a humidified atmosphere with 5% CO2. Activation of PBL with n-BP and IL-2 induced selective activation and proliferation of Vγ9Vδ2 T cells. Recombinant IL-2 (Novartis) was added every 2 days at a concentration of 50 IU/mL for 14 days, as initially stimulated γδ T cells produced only low levels of IL-2. After 14 days, the short-term activated γδ T cell lines were stained with the following antibodies: AF700-labeled anti-CD3 clone SK7 (BioLegend, San Diego, CA, USA); AF488-labeled anti-Vγ9 clone 7A5 (62) flow cytometry to determine purity. γδ T cells with a purity of >95% were used for functional assays”.
“A correction was also made to the Results section, Evobodies are first-in-class bispecific therapeutic antibodies that mimic an intracellular infection selectively at the tumor site:
This sentence was altered in error: “Comparing the cytotoxic responses of each candidate molecule against OVCAR-3 wild-type (WT) and FOLR1 KO cells allowed us to determine the respective therapeutic windows. window was determined.”
A correction has been made to the sentence: “Comparing the cytotoxic responses of each candidate molecule against OVCAR-3 wild-type (WT) and FOLR1 KO cells allowed us to determine the respective therapeutic window was determined.”
Additionally, a final error was made in the Results section, Evobodies mediate Vγ9Vδ2 T cellcytotoxicity against autologous ovarian tumor cells:
Part of this sentence was made redundant: “Understandably, for more than three decades Vγ9Vδ2 T cells have attracted the interest of many researchers and drug developers for over three decades (23).”
This sentence has now been corrected: “Understandably, Vγ9Vδ2 T cells have attracted the interest of many researchers and drug developers for over three decades (23).”
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Vγ9Vδ2 T cells, FOLR1, evobody, ovarian cancer, immunotherapy, BTN3A
Citation: Oberg H-H, Deseke M, Krohn S, Winterberg D, Peipp M, Bauerschlag D, Künkele K-P, Wesch D and Baumann C (2025) Correction: Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer. Front. Immunol. 16:1672018. doi: 10.3389/fimmu.2025.1672018
Received: 23 July 2025; Accepted: 29 August 2025;
Published: 12 September 2025.
Edited and reviewed by:
Cristiana Cairo, University of Maryland, United StatesCopyright © 2025 Oberg, Deseke, Krohn, Winterberg, Peipp, Bauerschlag, Künkele, Wesch and Baumann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Daniela Wesch, ZGFuaWVsYS53ZXNjaEB1a3NoLmRl; Christoph Baumann, Y2hyaXN0b3BoLmJhdW1hbm5AZXZvYnJpZ2h0LmNvbQ==
†These authors have contributed equally to this work and share first authorship